ArticleFolia microbiologica2026
Bioactivity and biosynthetic insights into Penicillium brefeldianum BPSRJ7, an endophyte associated with the ethnomedicinal orchid Dendrobium chrysotoxum lindl.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endophytic fungi are recognized as prolific sources of bioactive secondary metabolites with therapeutic potential, often complementing the pharmacological properties of their host plants. Dendrobium chrysotoxum, an ethnomedicinal orchid, has long been used in traditional healthcare practices for treating fever, infections, and general weakness; however, the contribution of their endophytic microbiota to these bioactivities remains largely unexplored. In this study, thirty endophytic fungal isolates were obtained from roots, stems, and leaves of D. chrysotoxum, representing seven morphologically distinct taxa. Comprehensive phytochemical profiling revealed the presence of alkaloids, phenolics, flavonoids, tannins, and terpenoids, with Penicillium brefeldianum BPSRJ7 consistently exhibiting the highest metabolite abundance across the tested isolates. Functional assays demonstrated that P. brefeldianum BPSRJ7 possessed strong antioxidant capacity, broad-spectrum antimicrobial activity, and selective cytotoxicity against MCF-7 and A549 cancer cells, while sparing non-malignant HEK-293 cells. FTIR and GC-MS analyses indicated the chemical complexity of P. brefeldianum BPSRJ7 metabolites, suggesting the presence of aromatic acids, phenolic derivatives, terpenoids, and lipophilic compounds. Biosynthetic gene analysis targeting the ketosynthase domain of Type I polyketide synthase (pks) genes predicted clusters associated with naphthopyrones, mitorubrinol, brefeldin A, and 1,3,6,8-tetrahydroxynaphthalene, underscoring its genetic potential for producing pharmacologically significant polyketides. Cell membrane disruption, evidenced by leakage of nucleic acids, proteins, and LDH in treated cells, suggested a preliminary mechanism underlying the antimicrobial and cytotoxic activities. This study highlights P. brefeldianum BPSRJ7 as a promising candidate for natural product discovery and underscores the importance of endophytic fungi in the pharmacological potential of traditional medicinal plants.
Indexed as
Identifiers
42329346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.